Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 15;16(1):1334.
doi: 10.1007/s12672-025-03189-5.

The role of long noncoding RNA SNHG29 in malignant tumors

Affiliations
Review

The role of long noncoding RNA SNHG29 in malignant tumors

Tingcheng Bu et al. Discov Oncol. .

Abstract

Long noncoding RNAs (lncRNAs), defined as noncoding transcripts exceeding 200 nucleotides without protein-coding potential, have been increasingly recognized for encoding polipeptides or proteinsimplicated in the regulation of malignant tumor initiation, progression, and prognosis. Among them, small nucleolar RNA host gene 29 (SNHG29) has attracted increasing attention because of its aberrant expression across diverse malignancies. This report reviews the latest research regarding its expression patterns, regulatory functions, and involved signaling pathways. This review synthesizes current insights into the contributions of SNHG29 to oncogenic processes, including cell proliferation, migration, epithelial‒mesenchymal transition, chemoresistance, and immunosuppression. Furthermore, evidence indicates that SNHG29 functions as a competing endogenous RNA (ceRNA), modulating tumor progression via the miRNA‒mRNA axis and signaling pathways such as the ATR‒Chk1, PI3K‒AKT, and Wnt‒β-catenin pathways. Cumulative data position SNHG29 as a promising diagnostic and prognostic biomarker, as well as a potential molecular target for therapeutic intervention in various malignancies.

Keywords: Biomarker; Human cancer; Long noncoding RNA; Prognosis; SNHG29.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: This is not applicable for this review. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Molecular mechanisms of SNHG29 in malignant tumors

Similar articles

References

    1. Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a. Cancer J Clin. 2024;74(3):229–63. - PubMed
    1. Cui C, et al. Functions and mechanisms of circular RNAs in cancer radiotherapy and chemotherapy resistance. Mol Cancer. 2020;19(1):58. - PMC - PubMed
    1. Chen B, et al. Targeting non-coding RNAs to overcome cancer therapy resistance. Signal Transduct Target Therapy. 2022;7(1):121. - PMC - PubMed
    1. Schmitt AM, Chang HY. Long noncoding RNAs cancer pathways. Cancer Cell. 2016;29(4):452–63. - PMC - PubMed
    1. Winkle M, et al. Noncoding RNA therapeutics - challenges and potential solutions. Nat Rev Drug Discov. 2021;20(8):629–51. - PMC - PubMed

LinkOut - more resources